EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market
Partner CStone Announces Positive NSCLC Results For Sugemalimab
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.
You may also be interested in...
China has fielded several homegrown checkpoint inhibitors, using lower cost as an argument for the US market, but sintilimab – a key test case – has underscored FDA skepticism.
Biopharma is entering a new period of intense competition from new sources, requiring a change in approach to portfolio strategy and lifecycle management.
New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.